An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function

Acute myeloid leukemia (AML) is a heterogeneous clonal disorder which has very poor overall survival, particularly relapsed and refractory AML [1]. The development of tumor-associated antigen-directed cytotoxic agents has opened a new door to improving treatment outcomes in these patients [2]. CD33 antigen is detected on blasts of over 90% of AML patients, making it a highly promising candidate for targeted therapy for AML [3 –6].

Source: Leukemia Research - October 1, 2018 Category: Hematology Authors: Yimamu Maimaitili, Aki Inase, Yoshiharu Miyata, Akihito Kitao, Yu Mizutani, Seiji Kakiuchi, Yohei Shimono, Yasuyuki Saito, Takashi Sonoki, Hironobu Minami, Hiroshi Matsuoka Tags: Research paper Source Type: research